Atherosclerosis in chronic kidney disease: The role of macrophages

Nature Reviews Nephrology

Volumn 7, Issue 1, 2011, Pages 45-54

  Kon, Valentina ^a   Linton, MacRae F ^a   Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DOWN REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; KIDNEY FAILURE; KIDNEY PARENCHYMA; MACROPHAGE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MACROPHAGES; MICE;

EID: 78650522874     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.157     Document Type: Review

References (171)

1. Foley, R. N.; Parfrey, P. S. & Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal diseasE. Am. J. Kidney DiS. 32 (Suppl.), S112-S119 (1998).
2. Mann, J. F.; Gerstein, H. C.; Pogue, J.; Bosch, J. & Yusuf, S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629-636 (2001).
3. Muntner, P.; He, J.; Hamm, L.; Loria, C. & whelton, P. K. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United StateS. J. Am. Soc. Nephrol. 13, 745-753 (2002).
4. Go, A. S.; Chertow, G. M.; Fan, D.; McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305 (2004).
5. Hillege, H.L.; et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106, 1777-1782 (2002).
6. Glass, C. K. & witztum, J. L. Atherosclerosis: the road ahead. Cell 104, 503-516 (2001).
7. Huo, Y. & Ley, K. Adhesion molecules and atherogenesiS. Acta Physiol. Scand. 173, 35-43 (2001).
8. Peters, w. & Charo, I. F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout micE. Curr. Opin. Lipidol. 12, 175-180 (2001).
9. Smith, J. D.; et al. Decreased atherosclerosis in mice deficient in both macrophage colonystimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci. USA 92, 8264-8268 (1995).
10. Michelsen, K. S.; et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004).
11. Mach, F.; et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosiS. Proc. Natl Acad. Sci. USA 94, 1931-1936 (1997).
12. Gupta, S.; et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out micE. J. Clin. Invest. 99, 2752-2761 (1997).
13. Pinderski, L. J.; et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypeS. Circ. ReS. 90, 1064-1071 (2002).
14. Endemann, G.; et al. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268, 11811-11816 (1993).
15. Kodama, T; et al. Type I macrophage scavenger receptor contains ?-helical and collagen-like coiled coilS. Nature 343, 531-535 (1990).
16. Babaev, V. R.; et al. Reduced atherosclerotic lesions in mice deficient for total or macrophagespecific expression of scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol. 20, 2593-2599 (2000).
17. Overton, C. D.; Yancey, P. G.; Major, A. S.; Linton, M. F. & Fazio, S. Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mousE. Circ. ReS. 100, 670-677 (2007).
18. Yancey, P. G.; et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23, 712-719 (2003).
19. Cuchel, M & Rader, D. J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113, 2548-2555 (2006).
20. Yancey, P. G.; Yu, H.; Linton, M. F. & Fazio, S. A pathway-dependent on ApoE, ApoAI, and ABCA1 determines formation of buoyant highdensity lipoprotein by macrophage foam cellS. Arterioscler. Thromb. Vasc. Biol. 27, 1123-1131 (2007).
21. Linton, M. F.; Atkinson, J. B. & Fazio, S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267, 1034-1037 (1995).
22. Fazio, S.; et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophageS. Proc. Natl Acad. Sci. USA 94, 4647-4652 (1997).
23. Trogan, E.; et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoEdeficient micE. Proc. Natl Acad. Sci. USA 103, 3781-3786 (2006).
24. Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25, 2255-2264 (2005).
25. Erbay, E.; et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosiS. Nat. Med. 15, 1383-1391 (2009).
26. Babaev, V. R.; et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosiS. Cell. Metab. 8, 492-501 (2008).
27. Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosiS. Nat. Rev. Immunol. 10, 36-46 (2010).
28. Yancey, P. G.; et al. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler. Thromb. Vasc. Biol. 30, 787-795 (2010).
29. Amann, K. Media calcification and intima calcification are distinct entities in chronic kidney diseasE. Clin. J. Am. Soc. Nephrol. 3, 1599-1605 (2008).
30. Miyagi, M.; et al. Impact of renal function on coronary plaque composition. Nephrol. Dial. Transplant. 25, 175-181 (2010).
31. Nicholls, S. J.; et al. Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates ?60 versus >60 ml/min/1.73 m2: a meta-analysis of intravascular ultrasound studieS. Am. J. Cardiol. 99, 813-816 (2007).
32. Rigatto, C.; et al. Atheroma progression in chronic kidney diseasE. Clin. J. Am. Soc. Nephrol. 4, 291-298 (2009).
33. Bro, S.; et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient micE. J. Am. Soc. Nephrol. 14, 2466-2474 (2003).
34. Bro, S.; Moeller, F.; Andersen, C. B.; Olgaard, K. & Nielsen, L. B. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient micE. J. Am. Soc. Nephrol. 15, 1495-1503 (2004).
35. Suganuma, E.; et al. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J. Am. Soc. Nephrol. 17, 433-441 (2006).
36. Bro, S.; Binder, C. J.; witztum, J. L.; Olgaard, K. & Nielsen, L. B. Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient micE. Arterioscler. Thromb. Vasc. Biol. 27, 1080-1086 (2007).
37. Buzello, M.; et al. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J. Am. Soc. Nephrol. 14, 311-316 (2003).
38. Massy, Z. A.; et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout micE. J. Am. Soc. Nephrol. 16, 109-116 (2005).
39. Carrero, J. J.; Yilmaz, M. I.; Lindholm, B. & Stenvinkel, P. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif. 26, 291-299 (2008).
40. Honda, H.; et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney DiS. 47, 139-148 (2006).
41. Pachaly, M. A.; et al. Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patientS. Blood Purif. 26, 204-210 (2008).
42. Stinghen, A. E.; et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney diseasE. Nephron Clin. Pract. 111, c117-c126 (2009).
43. Suliman, M. E.; Qureshi, A. R.; Heimbger, O.; Lindholm, B. & Stenvinkel, P. Soluble adhesion molecules in end-stage renal disease: a predictor of outcomE. Nephrol. Dial. Transplant. 21, 1603-1610 (2006).
44. Serradell, M; et al. Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cellS. Haematologica 87, 1053-1061 (2002).
45. Campean, V; et al. CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failurE. Atherosclerosis 190, 156-166 (2007).
46. Sela, S.; et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney diseasE. J. Am. Soc. Nephrol. 16, 2431-2438 (2005).
47. Yoon, J. W.; Pahl, M. V. & Vaziri, N. D. Spontaneous leukocyte activation and oxygenfree radical generation in end-stage renal diseasE. Kidney Int. 71, 167-172 (2007).
48. Pahl, M. V.; Vaziri, N. D.; Yuan, J. & Adler, S. G. Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal diseasE. Clin. J. Am. Soc. Nephrol. 5, 56-61 (2010).
49. Himmelfarb, J.; Stenvinkel, P.; Ikizler, T. A. & Hakim, R. M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 62, 1524-1538 (2002).
50. Kaysen, G. A. & Eiserich, J. P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J. Am. Soc. Nephrol. 15, 538-548 (2004).
51. Oberg, B. P.; et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney diseasE. Kidney Int. 65, 1009-1016 (2004).
52. Pupim, L. B.; Himmelfarb, J.; McMonagle, E.; Shyr, Y. & Ikizler, T. A. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stresS. Kidney Int. 65, 2371-2379 (2004).
53. DApolito, M.; et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failurE. J. Clin. Invest. 120, 203-213 (2010).
54. Touyz, R. M.; Yao, G.; Quinn, M. T.; Pagano, P. J. & Schiffrin, E. L. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 25, 512-518 (2005).
55. wang, Z.; et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesiS. Nat. Med. 13, 1176-1184 (2007).
56. Daganar, O.; et al. Plasma myeloperoxidase is related to the severity of coronary artery diseasE. Acta Cardiol. 63, 147-152 (2008).
57. Meuwese, M. C.; et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 50, 159-165 (2007).
58. Grahl, D. A.; et al. Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patientS. Blood Purif. 25, 210-218 (2007).
59. Pecoits-Filho, R.; et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patientS. Kidney Int. Suppl. 84, S172-S176 (2003).
60. Bro, S. Cardiovascular effects of uremia in apolipoprotein E-deficient micE. Dan. Med. Bull. 56, 177-192 (2009).
61. Ivanovski, O.; et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout micE. Kidney Int. 67, 2288-2294 (2005).
62. Boaz, M; et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356, 1213-1218 (2000).
63. Tepel, M.; van der Giet, M.; Statz, M.; Jankowski, J. & Zidek, w. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107, 992-995 (2003).
64. Himmelfarb, J.; et al. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patientS. J. Ren. Nutr. 17, 296-304 (2007).
65. Nanayakkara, P. W.; et al. Randomized placebocontrolled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am. J. Kidney DiS. 53, 41-50 (2009).
66. Mafra, D.; et al. Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patientS. Nephrol. Dial. Transplant. 24, 1587-1592 (2009).
67. Lee, I.M.; et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the womens Health Study: a randomized controlled trial. JAMA 294, 56-65 (2005).
68. Sesso, H.D.; et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians Health Study II randomized controlled trial. JAMA 300, 2123-2133 (2008).
69. Llodr J.; et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaqueS. Proc. Natl Acad. Sci. USA 101, 11779-11784 (2004).
70. williams, K. J.; Feig, J. E. & Fisher, E. A. Rapid regression of atherosclerosis: insights from the clinical and experimental literaturE. Nat. Clin. Pract. Cardiovasc. Med. 5, 91-102 (2008).
71. Trogan, E.; et al. Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 1714-1719 (2004).
72. Ponda, M.P.; Barash, I.; Feig, J. E.; Fisher, E. A. & Skolnik, E. Y. Moderate kidney disease inhibits atherosclerosis regression. Atherosclerosis 210, 57-62 (2010).
73. Osada, S.; et al. Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patientS. Nephrol. Dial. Transplant. 24, 3504-3512 (2009).
74. Yamamoto, Y.; et al. Possible involvement of increased glycoxidation and lipid peroxidation of elastin in atherogenesis in haemodialysis patientS. Nephrol. Dial. Transplant. 17, 630-636 (2002).
75. Nagao, T.; Qin, C.; Grosheva, I.; Maxfield, F. R. & Pierini, L. M. Elevated cholesterol levels in the plasma membranes of macrophages inhibit migration by disrupting RhoA regulation. Arterioscler. Thromb. Vasc. Biol. 27, 1596-1602 (2007).
76. Zerbinatti, C. V. & Gore, R. w. Uptake of modified low-density lipoproteins alters actin distribution and locomotor forces in macrophageS. Am. J. Physiol. Cell. Physiol. 284, C555-C561 (2003).
77. Chmielewski, M.; et al. Expression of scavenger receptor CD36 in chronic renal failure patientS. Artif. Organs 29, 608-614 (2005).
78. wu, C. C.; et al. Aberrant activation of the TNF-? system and production of Fas and scavenger receptors on monocytes in patients with endstage renal diseasE. Artif. Organs 29, 701-707 (2005).
79. Park, Y. M.; Febbraio, M. & Silverstein, R. L. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J. Clin. Invest. 119, 136-145 (2009).
80. Harb, D.; et al. The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc. ReS. 83, 42-51 (2009).
81. Kuchibhotla, S.; et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc. ReS. 78, 185-196 (2008).
82. Marleau, S.; et al. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesionS. FASEB J. 19, 1869-1871 (2005).
83. Ando, M.; Lundkvist, I.; Bergstr, J. & Lindholm, B. Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patientS. Kidney Int. 49, 773-780 (1996).
84. Kim, H. J.; Moradi, H.; Yuan, J.; Norris, K. & Vaziri, N. D. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol. Renal Physiol. 296, F1297-F1306 (2009).
85. Moradi, H.; Yuan, J.; Ni, Z.; Norris, K. & Vaziri, N. D. Reverse cholesterol transport pathway in experimental chronic renal failurE. Am. J. Nephrol. 30, 147-154 (2009).
86. Zager, R. A.; Johnson, A. C.; Hanson, S. Y. & Shah, V. O. Acute tubular injury causes dysregulation of cellular cholesterol transport proteinS. Am. J. Pathol. 163, 313-320 (2003).
87. Ando, M.; Gafvels, M.; Bergstr, J.; Lindholm, B. & Lundkvist, I. Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int. 51, 785-792 (1997).
88. Konishi, Y.; et al. Enhanced gene expression of scavenger receptor in peripheral blood monocytes from patients on cuprophane haemodialysiS. Nephrol. Dial. Transplant. 12, 1167-1172 (1997).
89. wang, X. & Rader, D. J. Molecular regulation of macrophage reverse cholesterol transport. Curr. Opin. Cardiol. 22, 368-372 (2007).
90. Yvan-Charvet, L.; wang, N. & Tall, A. R. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responseS. Arterioscler. Thromb. Vasc. Biol. 30, 139-143 (2010).
91. Zuo, Y.; et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler. Thromb. Vasc. Biol. 29, 1277-1282 (2009).
92. Cardinal, H.; Raymond, M. A.; Hebert, M. J. & Madore, F. Uraemic plasma decreases the expression of ABCA1, ABCG1 and cell-cycle genes in human coronary arterial endothelial cellS. Nephrol. Dial. Transplant. 22, 409-416 (2007).
93. Baranova, I.; et al. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAw cellS. Infect. Immun. 70, 2995-3003 (2002).
94. Chen, M.; Li, W.; wang, N.; Zhu, Y. & wang, X. ROS and NF-B but not LXR mediate IL-1? signaling for the downregulation of ATP-binding cassette transporter A1. Am. J. Physiol. Cell. Physiol. 292, C1493-C1501 (2007).
95. Ferreira, V; et al. Macrophage-specific inhibition of NF-κB activation reduces foam-cell formation. Atherosclerosis 192, 283-290 (2007).
96. Tang, C.; Kanter, J. E.; Bornfeldt, K. E.; Leboeuf, R. C. & Oram, J. F. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneyS. J. Lipid ReS. 51, 1719-1728 (2010).
97. wang, Y.; Kurdi-Haidar, B. & Oram, J. F. LXRmediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J. Lipid ReS. 45, 972-980 (2004).
98. Bohlender, J. M.; Franke, S.; Stein, G. & wolf, G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 289, F645-F659 (2005).
99. Pedersen, T.X.; et al. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient micE. Atherosclerosis 202, 372-381 (2009).
100. Francone, O. L.; et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1- deficient macrophageS. Arterioscler. Thromb. Vasc. Biol. 25, 1198-1205 (2005).
101. Zhu, X.; et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophageS. J. Biol. Chem. 283, 22930-22941 (2008).
102. Gollapudi, P.; Yoon, J. W.; Gollapudi, S.; Pahl, M. V. & Vaziri, N. D. Leukocyte toll-like receptor expression in end-stage kidney diseasE. Am. J. Nephrol. 31, 247-254 (2010).
103. Kuroki, Y.; et al. A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patientS. Int. J. Mol. Med. 19, 783-790 (2007).
104. Tsimikas, S.; et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery diseasE. N. Engl. J. Med. 353, 46-57 (2005).
105. Liu, J. & Rosner, M. H. Lipid abnormalities associated with end-stage renal diseasE. Semin. Dial. 19, 32-40 (2006). (Pubitemid 43479009)
106. Podrez, E. A.; et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen specieS. J. Clin. Invest. 105, 1095-1108 (2000).
107. Hakka S.; Huttunen, K.; Kervinen, K. & Kesiemi, Y. A. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur. J. Clin. Invest. 24, 105-113 (1994). (Pubitemid 24222972)
108. Fellstr, B. C.; et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysiS. N. Engl. J. Med. 360, 1395-1407 (2009).
109. wanner, C.; et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysiS. N. Engl. J. Med. 353, 238-248 (2005). (Pubitemid 41058323)
110. Tsimihodimos, V.; Dounousi, E. & Siamopoulos, K. C. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am. J. Nephrol. 28, 958-973 (2008).
111. Mekki, K.; Bouchenak, M.; Remaoun, M. & Belleville, J. L. Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study. Med. Sci. Monit. 10, CR439-CR446 (2004).
112. Moradi, H.; Pahl, M. V.; Elahimehr, R. & Vaziri, N. D. Impaired antioxidant activity of highdensity lipoprotein in chronic kidney diseasE. Transl. ReS. 153, 77-85 (2009).
113. Gugliucci, A.; et al. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patientS. Clin. Chim. Acta 384, 105-112 (2007).
114. Gugliucci, A.; et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearancE. Clin. Chim. Acta 377, 213-220 (2007).
115. Jurek, A.; Turyna, B.; Kubit, P. & Klein, A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failurE. Clin. Biochem. 39, 19-27 (2006).
116. Kalantar-Zadeh, K.; Kopple, J. D.; Kamranpour, N.; Fogelman, A. M. & Navab, M. HDL-inflammatory index correlates with poor outcome in hemodialysis patientS. Kidney Int. 72, 1149-1156 (2007).
117. Kronenberg, F.; Ikewaki, K.; Schaefer, J. R.; Konig, P. & Dieplinger, H. Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? Semin. Dial. 20, 554-560 (2007).
118. Vaziri, N. D.; Moradi, H.; Pahl, M. V.; Fogelman, A. M. & Navab, M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptidE. Kidney Int. 76, 437-444 (2009).
119. Wong, J.; Quinn, C. M.; Gelissen, I. C.; Jessup, w. & Brown, A. J. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 196, 180-189 (2008).
120. Shoji, T.; et al. Advanced atherosclerosis in predialysis patients with chronic renal failurE. Kidney Int. 61, 2187-2192 (2002).
121. Sone, H.; et al. Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophageS. Biochem. BiophyS. ReS. Commun. 316, 790-794 (2004).
122. Tamehiro, N.; et al. Sterol regulatory elementbinding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol statuS. J. Biol. Chem. 282, 21090-21099 (2007).
123. Argmann, C. A.; et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl- CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J. Biol. Chem. 280, 22212-22221 (2005).
124. Becker, L.; et al. A macrophage sterol-responsive network linked to atherogenesiS. Cell. Metab. 11, 125-135 (2010).
125. Qiu, G. & Hill, J. S. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J. Cardiovasc. Pharmacol. 51, 388-395 (2008).
126. Lewis, E. J.; Hunsicker, L. G.; Bain, R. P. & Rohde, R. D. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
127. Maschio, G.; et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939-945 (1996).
128. Baker, w. L.; et al. Systematic review: comparative effectiveness of angiotensinconverting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart diseasE. Ann. Intern. Med. 151, 861-871 (2009).
129. Yusuf, S.; et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientS. The Heart Outcomes Prevention Evaluation Study InvestigatorS. N. Engl. J. Med. 342, 145-153 (2000). (Pubitemid 30051645)
130. Ayabe, N; et al. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic micE. Atherosclerosis 184, 312-321 (2006).
131. da Cunha, V.; et al. Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosiS. J. Vasc. Surg. 44, 364-371 (2006).
132. da Cunha, V; et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178, 9-17 (2005).
133. Daugherty, A.; Manning, M. w. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient micE. J. Clin. Invest. 105, 1605-1612 (2000).
134. Sasaki, T; et al. AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient micE. Atherosclerosis 210, 430-437 (2010).
135. Xu, H. X.; et al. Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Acta Cardiol. 62, 607-613 (2007).
136. Nobuhiko, A.; et al. Angiotensin II amplifies macrophage-driven atherosclerosiS. Arterioscler. Thromb. Vasc. Biol. 24, 2143-2148 (2004).
137. Blessing, E; et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient micE. Atherosclerosis 199, 295-303 (2008).
138. Takahashi, M.; et al. Angiotensin II and tumor necrosis factor-β synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-κB, p38, and reactive oxygen specieS. Am. J. Physiol. Heart Circ. Physiol. 294, H2879-H2888 (2008).
139. Daugherty, A; Rateri, D. L.; Lu, H.; Inagami, T. & Cassis, L. A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110, 3849-3857 (2004).
140. Okamura, A.; et al. Upregulation of renin- angiotensin system during differentiation of monocytes to macrophageS. J. HypertenS. 17, 537-545 (1999).
141. Sales, V. L.; et al. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 112, 3328-3336 (2005).
142. Montecucco, F.; Pende, A. & Mach, F. The renin- angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studieS. Mediators Inflamm. doi:10.1155/2009/752406.
143. AbdAlla, S.; Lother, H.; Langer, A.; el Faramawy, Y. & Quitterer, U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosiS. Cell 119, 343-354 (2004).
144. Daffel, Y.; et al. Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis 157, 151-160 (2001).
145. Cassis, L. A.; Rateri, D. L.; Lu, H. & Daugherty, A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysmS. Arterioscler. Thromb. Vasc. Biol. 27, 380-386 (2007).
146. Fukuda, D.; Sata, M.; Ishizaka, N. & Nagai, R. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient micE. Arterioscler. Thromb. Vasc. Biol. 28, 90-96 (2008).
147. Lu, H.; et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in micE. J. Clin. Invest. 118, 984-993 (2008).
148. Tsubakimoto, Y.; et al. Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cellS. Arterioscler. Thromb. Vasc. Biol. 29, 1529-1536 (2009).
149. Ulrich, C.; Heine, G. H.; Seibert, E.; Fliser, D. & Girndt, M. Circulating monocyte subpopulations with high expression of angiotensin- converting enzyme predict mortality in patients with endstage renal diseasE. Nephrol. Dial. Transplant. 25, 2265-2272 (2010).
150. Nakaya, K.; et al. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPAR?. J. Atheroscler. Thromb. 14, 133-141 (2007).
151. Takata, Y.; et al. Transcriptional repression of ATPbinding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. Circ. ReS. 97, e88-e96 (2005).
152. wang, Y.; et al. Angiotensin II increases the cholesterol content of foam cells via downregulating the expression of ATP-binding cassette transporter A1. Biochem. BiophyS. ReS. Commun. 353, 650-654 (2007).
153. Takaya, T; et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient micE. Atherosclerosis 186, 402-410 (2006).
154. Yoshiyama, M.; et al. Angiotensin blockade inhibits increased JNKs, AP-1 and NF-κB DNAbinding activities in myocardial infarcted ratS. J. Mol. Cell. Cardiol. 33, 799-810 (2001).
155. Calkin, A.C.; et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 51, 1731-1740 (2008).
156. Koh, K.K.; Han, S. H.; Oh, P. C.; Shin, E. K. & Quon, M. J. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid- RAAS interaction. Atherosclerosis 209, 307-313 (2010).
157. Van Antwerpen, P.; et al. Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitorS. Eur. J. Pharmacol. 537, 31-36 (2006).
158. Kojima, C.; Ino, J.; Ishii, H.; Nitta, K. & Yoshida, M. MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation. J. Atheroscler. Thromb. 17, 97-105 (2010).
159. de Nigris, F.; et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout micE. Int. J. Cardiol. 81, 107-115 (2001).
160. Tokmakova, M.P.; et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 110, 3667-3673 (2004).
161. Li, P. K.; Chow, K. M.; wong, T. Y.; Leung, C. B. & Szeto, C. C. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysiS. A randomized, controlled study. Ann. Intern. Med. 139, 105-112 (2003).
162. Zannad, F.; et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studieS. Kidney Int. 70, 1318-1324 (2006).
163. Akbari, A.; et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and metaanalysis of randomized controlled trialS. Perit. Dial. Int. 29, 554-561 (2009).
164. Balamuthusamy, S.; et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysiS. Am. Heart J. 155, 791-805 (2008).
165. Berger, A. K.; Duval, S. & Krumholz, H. M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol. 42, 201-208 (2003).
166. Efrati, S.; et al. ACE inhibitors and survival of hemodialysis patientS. Am. J. Kidney DiS. 40, 1023-1029 (2002).
167. Fang, W.; Oreopoulos, D. G. & Bargman, J. M. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysiS. Nephrol. Dial. Transplant. 23, 3704-3710 (2008).
168. Hou, F. F.; et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131-140 (2006).
169. McCullough, P. A.; Sandberg, K. R.; Yee, J. & Hudson, M. P. Mortality
170. Suzuki, H.; et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am. J. Kidney DiS. 52, 501-506 (2008).
171. Takahashi, A.; et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol. Dial. Transplant. 21, 2507-2512 (2006).